Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Bristol Myers Squibb's Antibody Drug Achieves Success in China Trial
Bristol Myers Squibb and partner SystImmune’s antibody-drug conjugate, izalontamab brengitecan, successfully met dual primary endpoints in a Phase 3 trial for triple-negative breast cancer in China, marking a significant treatment breakthrough. This is the third late-stage success for the drug and the first bispecific ADC to achieve such results in this cancer type. The company solidified its confidence in the drug’s global market potential by signing an $8.4 billion licensing deal in 2023 to develop it outside of China.